Key Insights

Highlights

Treatment Research

9 treatments under study, led by Bedaquiline

Research Leaders

15 sponsors active, led by IQVIA RDS Inc.

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (2)

Trial Status

Recruiting1
Not Yet Recruiting1
Suspended1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07517445Phase 2SuspendedPrimary

Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

NCT07525427Phase 2RecruitingPrimary

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

NCT07608172Not ApplicableNot Yet Recruiting

Short-Course Regimens for DS-PTB in AIDS Patients

Showing all 3 trials

Research Network

Common Treatments

  • Bedaquiline2
  • Linezolid2
  • Pretomanid2
  • 2hpmz2hpm1
  • Bedaquiline Pretomanid And Linezolid1

Active Sponsors

  • IQVIA RDS Inc.2
  • Gates Medical Research Institute2
  • Chengdu Public Health Clinical Center1
  • Chest Hospital of Guangxi Zhuang Autonomous Region1
  • Beijing Ditan Hospital1

Top Investigators

Related Conditions

  • Tuberculosis In Hivinfected Individuals1

Activity Timeline